-
公开(公告)号:US12115220B2
公开(公告)日:2024-10-15
申请号:US17309186
申请日:2019-11-05
发明人: Mark A. Latta
IPC分类号: A61K36/00 , A61K9/00 , A61K31/02 , A61K31/045 , A61K31/047 , A61K31/085 , A61K31/14 , A61K31/155 , A61K31/167 , A61K31/221 , A61K31/245 , A61K31/4164 , A61K31/4178 , A61K31/4425 , A61K31/7036 , A61K31/714 , A61K31/717 , A61K33/00 , A61K33/06 , A61K33/16 , A61K33/30 , A61K33/40 , A61K33/42 , A61K35/644 , A61K36/185 , A61K36/28 , A61K36/484 , A61K36/537 , A61K36/889 , A61K38/12 , A61K47/34
CPC分类号: A61K47/34 , A61K9/006 , A61K31/02 , A61K31/045 , A61K31/047 , A61K31/085 , A61K31/14 , A61K31/155 , A61K31/167 , A61K31/221 , A61K31/245 , A61K31/4164 , A61K31/4178 , A61K31/4425 , A61K31/7036 , A61K31/714 , A61K31/717 , A61K33/00 , A61K33/06 , A61K33/16 , A61K33/30 , A61K33/40 , A61K33/42 , A61K35/644 , A61K36/185 , A61K36/28 , A61K36/484 , A61K36/537 , A61K36/889 , A61K38/12
摘要: An oral mucosal carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active agent.
-
公开(公告)号:US20240277607A1
公开(公告)日:2024-08-22
申请号:US18643713
申请日:2024-04-23
IPC分类号: A61K9/00 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/7004 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/14 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K36/48 , A61P3/02 , A61P3/12 , A61P3/14
CPC分类号: A61K9/0029 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/7004 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/14 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K36/48 , A61P3/02 , A61P3/12 , A61P3/14
摘要: A parenteral nutrition including at least one of an amino acid, a dextrose, a lipid, an electrolyte or a mixture thereof and a trace element including at least one of zinc, copper, selenium, or manganese is provided. The parenteral nutrition including the trace element is stable for about at least 3 days to about 14 days. Methods of preparing and using the stable injectable parenteral nutrition are also provided.
-
公开(公告)号:US20240269167A1
公开(公告)日:2024-08-15
申请号:US18258658
申请日:2021-12-20
发明人: Maher Atari Abouasi
IPC分类号: A61K33/14 , A61K9/00 , A61K9/08 , A61K31/192 , A61K31/4425 , A61K33/42 , A61P1/02 , A61P17/02
CPC分类号: A61K33/14 , A61K9/0043 , A61K9/006 , A61K9/08 , A61K31/192 , A61K31/4425 , A61K33/42 , A61P1/02 , A61P17/02
摘要: The use of a composition comprising a therapeutically effective amount of sodium dihydrogen phosphate and sodium chloride as mucosal re-epithelialization promoter, particularly to the oral, nasal, and paranasal mucosal. A composition comprising sodium dihydrogen phosphate, sodium chloride, potassium hydrogen phosphate, potassium chloride, calcium chloride, and a salt of a divalent metal different from calcium, particularly magnesium chloride; processes for their preparation; a kit containing it and its use as mucosal re-epithelialization promoter.
-
公开(公告)号:US20240245827A1
公开(公告)日:2024-07-25
申请号:US18405569
申请日:2024-01-05
发明人: Rui Ruan , Ming-Hao Zheng
CPC分类号: A61L27/12 , A61K33/06 , A61K33/42 , A61L27/3604 , A61L2400/06 , A61L2430/02 , A61L2430/12
摘要: The invention relates to a calcified tissue substitute and methods of manufacturing and use related thereto. The methods for manufacturing a calcified tissue substitute include reacting ground nacre, monocalcium phosphate, and water to produce brushite; grinding the brushite; reacting ground nacre with the ground brushite disodium hydrogen phosphate solution. Methods for repairing and/or strengthening a calcified tissue in need thereof are provided, as well as a delivery device for delivering the calcified tissue substitute.
-
公开(公告)号:US11999653B2
公开(公告)日:2024-06-04
申请号:US17832208
申请日:2022-06-03
申请人: CORNING INCORPORATED
CPC分类号: C03C3/097 , A61K33/42 , C03C4/0014 , C03C4/0021 , C03C13/00 , C03B37/02 , C03B37/022 , C03C2204/00 , C03C2213/00 , C03C2213/02
摘要: Methods of making a bioactive glass fiber include forming a melt of a glass composition including: 50 to 70% SiO2; 0.1 to 10% Al2O3, 5 to 30% Na2O, 0.1 to 15% K2O, 0.1 to 15% MgO, 0.1 to 20% CaO, and 5 to 10% P2O5, based on a 100 wt % of the glass composition. The melt has a viscosity of from 200 Poise to 2,000 Poise. Methods include drawing the melt into a drawn glass fiber. Bioactive glass compositions include: 60 to 70% SiO2; 15 to 30% Na2O, 5 to 15% K2O, 1 to 10% CaO, and 5 to 10% P2O5, based on a 100 wt % of the glass composition.
-
公开(公告)号:US20240156696A1
公开(公告)日:2024-05-16
申请号:US18511294
申请日:2023-11-16
发明人: Yuwei FAN , Lina Fahad N. MENGARI , Zhi SUN
CPC分类号: A61K8/21 , A61K8/24 , A61K8/36 , A61K31/185 , A61K33/06 , A61K33/16 , A61K33/42 , A61Q11/00 , A61K2800/596 , A61K2800/805 , A61K2800/92
摘要: The present disclosure relates to compositions and methods for restoring enamel, e.g., on tooth surfaces.
-
公开(公告)号:US20240148782A1
公开(公告)日:2024-05-09
申请号:US18514612
申请日:2023-11-20
发明人: Markus Mandler , Achim Schneeberger , Wolfgang Zauner , Arne Von Bonin , Frank Mattner , Walter Schmidt
摘要: The invention discloses an aluminium salt for use in the treatment and prevention of dementias associated with β-amyloid deposition, preferably AD.
-
公开(公告)号:US11963992B2
公开(公告)日:2024-04-23
申请号:US17379255
申请日:2021-07-19
发明人: Per-Arne Öckerman
IPC分类号: A61K31/07 , A23L33/105 , A23L33/115 , A23L33/135 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/175 , A61K31/01 , A61K31/015 , A61K31/122 , A61K31/14 , A61K31/197 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/4188 , A61K31/4415 , A61K31/455 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/59 , A61K31/593 , A61K31/7004 , A61K31/714 , A61K33/06 , A61K33/14 , A61K33/18 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K35/60 , A61K35/744 , A61K35/747 , A61K36/45 , A61K36/752
CPC分类号: A61K36/752 , A23L33/105 , A23L33/115 , A23L33/135 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/175 , A61K31/01 , A61K31/015 , A61K31/07 , A61K31/122 , A61K31/14 , A61K31/197 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/4188 , A61K31/4415 , A61K31/455 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/59 , A61K31/593 , A61K31/7004 , A61K31/714 , A61K33/06 , A61K33/14 , A61K33/18 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K35/60 , A61K35/744 , A61K35/747 , A61K36/45 , A23V2002/00 , A61K35/60 , A61K2300/00 , A61K36/752 , A61K2300/00 , A61K35/744 , A61K2300/00 , A61K35/747 , A61K2300/00 , A61K36/45 , A61K2300/00 , A61K31/07 , A61K2300/00 , A61K31/01 , A61K2300/00 , A61K31/122 , A61K2300/00 , A61K31/14 , A61K2300/00 , A61K31/197 , A61K2300/00 , A61K31/198 , A61K2300/00 , A61K31/355 , A61K2300/00 , A61K31/375 , A61K2300/00 , A61K31/4188 , A61K2300/00 , A61K31/4415 , A61K2300/00 , A61K31/455 , A61K2300/00 , A61K31/51 , A61K2300/00 , A61K31/519 , A61K2300/00 , A61K31/525 , A61K2300/00 , A61K31/593 , A61K2300/00 , A61K31/7004 , A61K2300/00 , A61K31/714 , A61K2300/00 , A61K31/59 , A61K2300/00 , A61K31/015 , A61K2300/00 , A61K33/06 , A61K2300/00 , A61K33/18 , A61K2300/00 , A61K33/24 , A61K2300/00 , A61K33/42 , A61K2300/00 , A61K33/14 , A61K2300/00 , A61K33/34 , A61K2300/00 , A61K33/30 , A61K2300/00 , A61K33/32 , A61K2300/00 , A23V2002/00 , A23V2200/3204 , A23V2200/326 , A23V2250/06 , A23V2250/156 , A23V2250/1882 , A23V2250/211 , A23V2250/2116 , A23V2250/702 , A23V2250/704 , A23V2250/708 , A23V2250/71 , A23V2250/712 , A23V2250/714
摘要: Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease.
-
公开(公告)号:US20240000940A1
公开(公告)日:2024-01-04
申请号:US18039728
申请日:2021-11-30
申请人: NANOBIOTIX S.A.
CPC分类号: A61K41/0038 , A61P35/00 , A61N5/1001 , A61K33/42 , B82Y5/00 , A61N2005/1098
摘要: The invention concerns a particle and a composition comprising particles and their use in oncology. Specifically, the particles are porous, high-Z and carbon-free particles having internal pores, of longest dimension of at least 0.5 nm, and are for use in altering or destroying target cells in a mammal when said cells are exposed to ionizing radiation.
The present invention also provides a porous, high-Z and carbon-free particle wherein at least part of the porous structure of the particle is occupied by at least one therapeutic agent which is preferably for use in oncology.-
公开(公告)号:US20230390455A1
公开(公告)日:2023-12-07
申请号:US18454753
申请日:2023-08-23
发明人: Rui Ruan , Ming-Hao Zheng
CPC分类号: A61L27/12 , A61K33/06 , A61K33/42 , A61L27/3604 , A61L2400/06 , A61L2430/02 , A61L2430/12
摘要: The invention relates to a method for manufacturing a calcified tissue substitute, the method comprising: reacting ground nacre, monocalcium phosphate, and water to produce brushite; grinding the brushite; reacting ground nacre with the ground brushite in disodium hydrogenphosphate solution. The invention also relates to a calcified tissue substitute manufactured by the method, use of the calcified tissue substitute for repairing a calcified tissue, and a delivery device for delivering the calcified tissue.
-
-
-
-
-
-
-
-
-